Zusduri Approved for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer

The FDA has approved Zusduri for adult patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.